Dr. William Oh, an internationally recognized medical oncologist, has joined Sema4 as Chief Medical Science Officer. Dr. Oh brings more than 25 years of clinical and translational research experience.
Merus and Sema4 are utilizing Sema4’s genomic testing to identify patients with tumors harboring neuregulin 1 gene fusions who may be eligible for investigational treatment with the bispecific antibody Zenocutuzumab in a trial sponsored by Merus.
NBC Connecticut interviewed Sema4 President & COO Jamie Coffin on the opening of Sema4’s new 70,000 square foot facility in Stamford, CT. Among other things, the story covered Sema4’s growth and the jobs the company is generating in Connecticut.
NBC Connecticut featured Sema4’s COVID-19 testing during its evening news broadcast. NBC Connecticut included comments from Sema4 Founder and CEO Eric Schadt and highlighted the support Sema4 is providing to the State of Connecticut during the pandemic.
Sema4 has landed its first outside investment, allowing it to continue its rapid growth. Sema4 updated its investors webpage to include five new entities: private equity behemoth Blackstone; venture capital funds Section 32, OakHC/FT, and Decheng Capital; and Connecticut Innovations, the state’s quasi-public investment agency.